Differences in CD4 count increases in veterans starting antiretroviral therapy with lopinavir/ritonavir or efavirenz
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Differences in CD4 count increases in veterans starting antiretroviral therapy with lopinavir/ritonavir or efavirenz ; volume:11 ; number:1 ; day:10 ; month:11 ; year:2008 ; pages:1-2 ; date:12.2008
Journal of the International AIDS Society / International AIDS Society ; 11, Heft 1 (10.11.2008), 1-2, 12.2008
- Urheber
-
Bedimo, RJ
- Beteiligte Personen und Organisationen
-
Drechsler, H.
Holodniy, M.
Pasley, M.
Woodward, W.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-11-S1-P9
- URN
-
urn:nbn:de:1111-2016052054024
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bedimo, RJ
- Drechsler, H.
- Holodniy, M.
- Pasley, M.
- Woodward, W.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir
Lopinavir- und Efavirenz-Serumkonzentrationen bei antiretroviral behandelten HIV-infizierten Kindern in Südafrika
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Experience with ritonavir/atazanavir in HIV-positive antiretroviral-naïve individuals commencing therapy
O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients
Development of Efavirenz nanoparticle for enhanced efficiency of anti-retroviral therapy against HIV and AIDS
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir
Lopinavir- und Efavirenz-Serumkonzentrationen bei antiretroviral behandelten HIV-infizierten Kindern in Südafrika
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Experience with ritonavir/atazanavir in HIV-positive antiretroviral-naïve individuals commencing therapy
O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients
Development of Efavirenz nanoparticle for enhanced efficiency of anti-retroviral therapy against HIV and AIDS
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir
Lopinavir- und Efavirenz-Serumkonzentrationen bei antiretroviral behandelten HIV-infizierten Kindern in Südafrika
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Experience with ritonavir/atazanavir in HIV-positive antiretroviral-naïve individuals commencing therapy
O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients
Development of Efavirenz nanoparticle for enhanced efficiency of anti-retroviral therapy against HIV and AIDS
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study